How many insider trades does FilingIQ track for XERS?

FilingIQ tracks 310 Form 4 insider transactions for XERS (Xeris Biopharma Holdings, Inc.), covering filings from Jun 25, 2018 onwards. 14 of those were filed in the last 90 days.

Are XERS insiders net buyers or net sellers?

Across the full Form 4 history for XERS, 39 transactions (13%) were open-market purchases and 41 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does XERS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is XERS in?

Xeris Biopharma Holdings, Inc. (XERS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.10B.

XERS insider trading

NasdaqGS Healthcare

Xeris Biopharma Holdings, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

310

Last 90 days

Buys / sells

13% / 13%

Market cap

$1.10B

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Company website: www.xerispharma.com

XERS insider activity at a glance

FilingIQ has scored 310 insider transactions for XERS since Jun 25, 2018. The most recent filing in our index is dated May 1, 2026.

Across the full history, 39 open-market purchases and 41 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on XERS insider trades is 55.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live XERS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for XERS?: FilingIQ tracks 310 Form 4 insider transactions for XERS (Xeris Biopharma Holdings, Inc.), covering filings from Jun 25, 2018 onwards. 14 of those were filed in the last 90 days.
Are XERS insiders net buyers or net sellers?: Across the full Form 4 history for XERS, 39 transactions (13%) were open-market purchases and 41 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does XERS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is XERS in?: Xeris Biopharma Holdings, Inc. (XERS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.10B.

Methodology & sources

Every XERS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.